Loading clinical trials...
Loading clinical trials...
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Conditions
Interventions
Olaratumab
Gemcitabine
+2 more
Locations
48
United States
UCLA Medical Center
Santa Monica, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Mayo Clinic-Jacksonville
Jacksonville, Florida, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Georgia Cancer Specialists PC
Atlanta, Georgia, United States
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Start Date
March 1, 2016
Primary Completion Date
July 28, 2020
Completion Date
April 27, 2021
Last Updated
May 9, 2022
NCT06422806
NCT05108298
NCT06905132
NCT07156565
NCT02701153
NCT07432932
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions